Breaking News Instant updates and real-time market news.

RTRX

Retrophin

$20.08

-1.31 (-6.12%)

14:40
11/20/16
11/20
14:40
11/20/16
14:40

Retrophin reports additional Phase 2 data on sparsentan in glomerulosclerosis

Retrophin announced additional results from the Phase 2 DUET study of sparsentan for the treatment of focal segmental glomerulosclerosis, a rare kidney disorder. The new findings are being presented at the American Society of Nephrology Kidney Week. As announced in September, top-line data from DUET showed the sparsentan treatment group achieved statistical significance in the study's primary efficacy endpoint, reduction of proteinuria. An analysis of the secondary endpoint presented Saturday showed that a "significantly greater" proportion of patients receiving sparsentan achieved modified partial remission of proteinuria versus irbesartan patients. In addition, four patients receiving sparsentan achieved complete remission as compared to zero irbesartan patients. Also presented Saturday was a post-hoc, intention-to-treat analysis showing that the sparsentan treatment group again demonstrated a greater than two-fold reduction of proteinuria versus irbesartan. Further analysis of the safety database from the initial eight-week, double-blind treatment period also showed sparsentan was generally safe and well-tolerated. Detailed results of the above-mentioned findings include: "An analysis of the secondary endpoint, which showed that after the eight-week, double-blind treatment period, 28.1% of patients receiving sparsentan achieved modified partial remission of proteinuria, compared to 9.4% of irbesartan-treated patients. The proportion of patients achieving modified partial remission increased during the open label period. After 48 weeks of treatment with sparsentan, 57.7% of patients achieved modified partial remission. In addition, 50% of patients that transferred from irbesartan to sparsentan at the beginning of the open label period achieved modified partial remission after 40 weeks of treatment. Complete remission, defined as proteinuria less than 0.3 g/g, was achieved by four patients receiving sparsentan during the eight-week, double-blind treatment period, compared to zero irbesartan-treated patients. A post-hoc ITT analysis showed a statistically significant difference in the mean reduction of proteinuria from baseline for the sparsentan treatment group compared to the irbesartan group after the study's eight-week, double-blind treatment period. The sparsentan group achieved a 42.7% mean reduction of proteinuria compared to 15.7% for the irbesartan group. The ITT analysis also showed that after eight weeks of treatment with 400 mg and 800 mg of sparsentan, the mean reduction of proteinuria from baseline was 44.8%, compared to 15.9% for the irbesartan-treated patients in these two cohorts. During the eight-week, double-blind period, the incidence of treatment-emergent adverse events for the sparsentan group was similar to the irbesartan group, except for edema. The severity of edema did not significantly worsen from baseline and no patients withdrew from the study as a result of edema during the eight-week, double-blind treatment period... The incidence of serious adverse events was similar across both groups. Eighty-four percent of patients who completed the eight-week, double-blind treatment period continue to receive sparsentan in the open-label extension."

RTRX Retrophin
$20.08

-1.31 (-6.12%)

09/07/16
ROTH
09/07/16
NO CHANGE
Target $151
ROTH
Buy
Ligand target raised to $151 after sparsentan data at Roth Capital
Roth Capital analyst Joseph Pantginis raised his price target for Ligand Pharmaceuticals (LGND) to $151 from $149 after the company's partner Retrophin (RTRX) announced positive data from the sparsentan Phase II study in focal segmental glomerulosclerosis patients. The analyst believes the data support a potential accelerated path forward and he reminds investors that FSGS has no approved therapies. Pantginis calls the data an important win for Ligand and Retrophin. He keeps a Buy rating on Ligand. The stock is up 7% to $115.21 in early trading.
09/07/16
LEER
09/07/16
NO CHANGE
LEER
Outperform
Retrophin price target raised to $32 from $27 at Leerink
Leerink analyst Joseph Schwartz said he is "very optimistic" that sparsentan will be approved after Retrophin announced top-line results for its Phase 2b DUET study. However, he thinks it is still unclear if the results reported today will be enough to support accelerated approval or if another clinical trial will be required. Schwartz raised his price target on Retrophin to $32 from $27 following the data release and keeps an Outperform rating on the shares.
09/08/16
BMOC
09/08/16
NO CHANGE
BMOC
Retrophin price target raised to $40 from $28 at BMO Capital
BMO Capital analyst Do Kim raised the price target on Retrophin after the company reported Phase II data for its Sparsentan drug that the analyst views positively. Kim now sees a 45% chance of success for the drug, up from 25% previously. The analyst keeps an Outperform rating on the shares.
11/11/16
LEER
11/11/16
NO CHANGE
LEER
Outperform
Retrophin agreement for RE-024 bodes well for approval in 2019, says Leerink
Leerink analyst Joseph Schwartz says that the trial design for Retrophin's pending Phase 3 trial of RE-024 and the announced agreement with the FDA under the Special Protocol Assessment process for this trial bode well for potential approval in 2019. The analyst believes the company plans to initiate this trial by the end of 2016, with a drug that has shown "great promise" for the treatment of pantothenate kinase-associated neurodegeneration. He reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

ELLO

Ellomay Capital

$8.05

0.0019 (0.02%)

14:33
04/30/17
04/30
14:33
04/30/17
14:33
Hot Stocks
Ellomay Capital enters agreement to acquire Talasol Solar »

Ellomay Capital announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GLPG

Galapagos NV

$86.86

0.87 (1.01%)

14:23
04/30/17
04/30
14:23
04/30/17
14:23
Hot Stocks
Galapagos presents preclinical data on osteoarthritis candidate GLPG1972 »

Galapagos announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 06

    Jun

SO

Southern Company

$49.80

-0.27 (-0.54%)

, TOSBF

Toshiba, also use TOSYY

$2.03

0.06 (3.05%)

14:16
04/30/17
04/30
14:16
04/30/17
14:16
Hot Stocks
Southern Co subsidiary extends interim agreement for Vogtle nuclear expansion »

Georgia Power and…

SO

Southern Company

$49.80

-0.27 (-0.54%)

TOSBF

Toshiba, also use TOSYY

$2.03

0.06 (3.05%)

TOSYY

Toshiba, also use TOSBF

$12.14

0.25 (2.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    May

  • 24

    May

CG

Carlyle Group

$17.70

0.2 (1.14%)

14:10
04/30/17
04/30
14:10
04/30/17
14:10
Hot Stocks
Sequa completes recapitalization with participation from Carlyle Group »

Sequa Corp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IBM

IBM

$160.29

-0.03 (-0.02%)

14:07
04/30/17
04/30
14:07
04/30/17
14:07
Hot Stocks
IBM says granted patent for drone package transfer »

IBM announced Friday that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRAM

Grana y Montero

$3.37

0.07 (2.12%)

14:05
04/30/17
04/30
14:05
04/30/17
14:05
Hot Stocks
Grana y Montero completes sale of PRINSUR stake for $25M »

Grana y Montero announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$43.15

0.14 (0.33%)

13:49
04/30/17
04/30
13:49
04/30/17
13:49
Hot Stocks
Coca-Cola Bottling UNITED says closes Georgia transaction with Coca-Cola »

Coca-Cola Bottling…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

VZ

Verizon

$45.91

-0.76 (-1.63%)

, T

AT&T

$39.63

-0.28 (-0.70%)

13:06
04/30/17
04/30
13:06
04/30/17
13:06
Periodicals
Business tax cut would favor telecoms, retailers, other sectors, Barron's says »

Sectors favored under a…

VZ

Verizon

$45.91

-0.76 (-1.63%)

T

AT&T

$39.63

-0.28 (-0.70%)

JPM

JPMorgan

$87.00

-0.61 (-0.70%)

COF

Capital One

$80.38

-1.93 (-2.34%)

CMA

Comerica

$70.70

-0.05 (-0.07%)

GPS

Gap

$26.20

-0.15 (-0.57%)

JWN

Nordstrom

$48.27

-0.03 (-0.06%)

BRK.A

Berkshire Hathaway

$247,780.00

-2170 (-0.87%)

BRK.B

Berkshire Hathaway

$165.21

-1.34 (-0.80%)

ANTM

Anthem

$177.89

-0.41 (-0.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    May

  • 09

    May

  • 09

    May

  • 16

    May

  • 17

    May

  • 17

    May

  • 18

    May

  • 19

    May

  • 31

    May

  • 06

    Jun

  • 14

    Jul

  • 12

    Oct

  • 13

    Apr

  • 13

    Jul

  • 12

    Oct

CMG

Chipotle

$474.47

-7.53 (-1.56%)

12:59
04/30/17
04/30
12:59
04/30/17
12:59
Periodicals
Chipotle remains unattractive, Barron's says »

Investors should continue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESRX

Express Scripts

$61.34

-0.06 (-0.10%)

, ANTM

Anthem

$177.89

-0.41 (-0.23%)

12:45
04/30/17
04/30
12:45
04/30/17
12:45
Periodicals
Express Scripts contract-loss warning suggests further pain, Barron's says »

Express Scripts'…

ESRX

Express Scripts

$61.34

-0.06 (-0.10%)

ANTM

Anthem

$177.89

-0.41 (-0.23%)

CVS

CVS Health

$82.44

-0.35 (-0.42%)

UNH

UnitedHealth

$174.88

0.25 (0.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 10

    May

  • 18

    May

  • 31

    May

  • 06

    Jun

LITE

Lumentum

$42.75

-1.05 (-2.40%)

, OCLR

Oclaro

$8.01

0.08 (1.01%)

12:38
04/30/17
04/30
12:38
04/30/17
12:38
Periodicals
Bargain-priced fiberoptic space looks attractive, Barron's says »

Fiberoptic stocks…

LITE

Lumentum

$42.75

-1.05 (-2.40%)

OCLR

Oclaro

$8.01

0.08 (1.01%)

NPTN

NeoPhotonics

$7.76

-0.19 (-2.39%)

FNSR

Finisar

$22.84

0.27 (1.20%)

ACIA

Acacia Communications

$45.84

-0.76 (-1.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 04

    May

  • 05

    May

  • 09

    May

  • 09

    May

  • 23

    May

  • 24

    May

  • 25

    May

  • 30

    May

COH

Coach

$39.39

-0.43 (-1.08%)

12:14
04/30/17
04/30
12:14
04/30/17
12:14
Periodicals
Coach could reserve course, Barron's says »

Retail accessory makers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

, PG

Procter & Gamble

$87.33

-0.36 (-0.41%)

12:08
04/30/17
04/30
12:08
04/30/17
12:08
Periodicals
Bargain-priced Edgewell could attract suitor, Barron's says »

Edgewell Personal Care…

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

PG

Procter & Gamble

$87.33

-0.36 (-0.41%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

NEE

NextEra Energy

$133.56

0.04 (0.03%)

11:58
04/30/17
04/30
11:58
04/30/17
11:58
Periodicals
NextEra Energy could return 20% in a year, Barron's says »

NextEra Energy appears…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    May

CAT

Caterpillar

$102.26

-0.42 (-0.41%)

11:52
04/30/17
04/30
11:52
04/30/17
11:52
Periodicals
Caterpillar shares 'back on track' for price gains, Barron's says »

Caterpillar is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 14

    Jun

RYN

Rayonier

$28.22

-0.39 (-1.36%)

, LL

Lumber Liquidators

$24.55

0.19 (0.78%)

08:21
04/30/17
04/30
08:21
04/30/17
08:21
Hot Stocks
Week in review: How Trump's policies moved stocks »

Catch up on the top…

RYN

Rayonier

$28.22

-0.39 (-1.36%)

LL

Lumber Liquidators

$24.55

0.19 (0.78%)

DEL

Deltic Timber

$77.37

-2.24 (-2.81%)

WY

Weyerhaeuser

$33.87

-0.8 (-2.31%)

OSB

Norbord

$31.07

0.23 (0.75%)

PCH

Potlatch

$45.05

-1.9 (-4.05%)

UFPI

Universal Forest

$95.29

-1.92 (-1.98%)

AA

Alcoa

$33.73

-0.79 (-2.29%)

KALU

Kaiser Aluminum

$84.41

-0.15 (-0.18%)

CENX

Century Aluminum

$13.64

-0.36 (-2.57%)

NFLX

Netflix

$152.20

-0.88 (-0.57%)

FB

Facebook

$150.25

2.55 (1.73%)

AMZN

Amazon.com

$924.99

6.61 (0.72%)

GOOG

Alphabet

$905.96

31.71 (3.63%)

GOOGL

Alphabet Class A

$924.52

33.08 (3.71%)

CMCSA

Comcast

$39.19

-0.4 (-1.01%)

CMCSK

Comcast

VZ

Verizon

$45.91

-0.76 (-1.63%)

T

AT&T

$39.63

-0.28 (-0.70%)

CYH

Community Health

$8.61

0.18 (2.14%)

HCA

HCA Holdings

$84.21

0.77 (0.92%)

LPNT

LifePoint

$62.15

1.4 (2.30%)

THC

Tenet

$15.67

0.2 (1.29%)

UHS

Universal Health

$120.76

2.55 (2.16%)

AET

Aetna

$135.07

1.09 (0.81%)

ANTM

Anthem

$177.89

-0.41 (-0.23%)

CNC

Centene

$74.40

1.45 (1.99%)

CI

Cigna

$156.37

0.16 (0.10%)

HNT

Health Net

HUM

Humana

$221.98

3.31 (1.51%)

MOH

Molina Healthcare

$49.79

1.16 (2.39%)

UNH

UnitedHealth

$174.88

0.25 (0.14%)

WCG

WellCare

$153.41

0.03 (0.02%)

HRB

H&R Block

$24.79

0.52 (2.14%)

INTU

Intuit

$125.21

-0.4 (-0.32%)

ATW

Atwood Oceanics

$7.83

-0.01 (-0.13%)

DO

Diamond Offshore

$14.42

-0.07 (-0.48%)

NE

Noble Corp.

$4.80

-0.03 (-0.62%)

NADL

North Atlantic Drilling

$2.53

0.18 (7.66%)

PACD

Pacific Drilling

$1.70

-0.07 (-3.95%)

RDC

Rowan Companies

$14.07

0.07 (0.50%)

SDRL

Seadrill

$0.69

0.0221 (3.31%)

FSLR

First Solar

$29.55

0.11 (0.37%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 01

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 02

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 03

    May

  • 04

    May

  • 04

    May

  • 04

    May

  • 05

    May

  • 05

    May

  • 08

    May

  • 08

    May

  • 09

    May

  • 09

    May

  • 09

    May

  • 10

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 16

    May

  • 17

    May

  • 17

    May

  • 18

    May

  • 22

    May

  • 23

    May

  • 23

    May

  • 24

    May

  • 25

    May

  • 31

    May

  • 05

    Jun

  • 06

    Jun

  • 13

    Jun

KBR

KBR

$14.05

-1.43 (-9.24%)

18:47
04/28/17
04/28
18:47
04/28/17
18:47
Hot Stocks
KBR issues statement on SFO investigation »

KBR made the following…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

SMMT

Summit Therapeutics

$11.00

-0.4 (-3.51%)

18:32
04/28/17
04/28
18:32
04/28/17
18:32
Hot Stocks
Summit Therapeutics publishes results from CoDIFy trial online »

Summit Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TKPYY

Takeda Pharmaceutical Co. Ltd.

$24.83

0.85 (3.54%)

18:14
04/28/17
04/28
18:14
04/28/17
18:14
Hot Stocks
Takeda says FDA grants accelerated approval of ALUNBRIG »

Takeda Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNBC

First NBC Bank

$2.65

-0.2 (-7.02%)

18:07
04/28/17
04/28
18:07
04/28/17
18:07
Hot Stocks
FDIC named receiver of First NBC Bank »

First NBC Bank, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGBK

Stonegate Bank

$45.90

-0.52 (-1.12%)

17:47
04/28/17
04/28
17:47
04/28/17
17:47
Earnings
Stonegate Bank reports Q1 non-GAAP EPS 56c, consensus 57c »

Reports Q1 NII $25.89M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PROV

Provident Financial

$19.23

-0.03 (-0.16%)

17:45
04/28/17
04/28
17:45
04/28/17
17:45
Hot Stocks
Provident Financial announces extension of stock repurchase plan »

Provident Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

YGE

Yingli Green Energy

$2.66

-0.03 (-1.12%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Yingli Green Energy files extension for 2016 Form 20-F filing »

Yingli Green Energy has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EPC

Edgewell Personal Care

$71.49

-0.14 (-0.20%)

17:40
04/28/17
04/28
17:40
04/28/17
17:40
Hot Stocks
Breaking Hot Stocks news story on Edgewell Personal Care »

Gabelli raises stake in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

ORC

Orchid Island Capital

$10.60

-0.33 (-3.02%)

17:35
04/28/17
04/28
17:35
04/28/17
17:35
Syndicate
Breaking Syndicate news story on Orchid Island Capital »

Orchid Island Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 13

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.